Search - tctmd.com

Displaying 1 - 15 of 15

Sort: Relevancy | Date

Presentation THT Abstracts 2025

Beta-Blocker Therapy and Long-Term Outcomes in Heart Failure With Reduced Ejection Fraction After Heart Transplantation: Real-World Evidence

Presenter: Thitiphan Srikulmontri

February 11, 2025

Presentation THT Abstracts 2025

Leveraging Remote Patient Monitoring to Optimize Guideline-Directed Medical Therapy in Heart Failure With Reduced Ejection Fraction

Presenter: Qianlan Xi

February 11, 2025

Presentation THT Abstracts 2025

Baroreflex Activation Therapy Improves Cardiopulmonary Exercise Tolerance and Aerobic Capacity in Heart Failure With Reduced Ejection Fraction

Presenter: Dmitry Yaranov

February 11, 2025

Presentation THT Abstracts 2025

Evaluating Glucagon-Like Peptide Agonists and Glucose-Dependent Insulinotropic Polypeptide Receptor Agonists Treatment in Heart Failure With Preserved Ejection Fraction: A Meta-Analysis of Global RCTs

February 11, 2025

Presentation THT Abstracts 2025

Association of SGLT2 Inhibitors With Clinical Outcomes in Patients With Severe Renal Impairment (Estimated Glomerular Filtration Rate < 30) and Heart Failure With Reduced Ejection Fraction (HFrEF)

Presenter: Jonathan Zawadzki

February 11, 2025

Presentation THT Abstracts 2025

Impact of Sitagliptin on Long-Term Outcomes in Heart Failure With Reduced Ejection Fraction in Type 2 Diabetes Patients: A Retrospective Cohort Study

Presenter: Thitiphan Srikulmontri

February 11, 2025

Presentation THT Abstracts 2025

Impact of Psychological Comorbidities on Clinical Outcomes in Heart Failure With Reduced Ejection Fraction (HFrEF)

Presenter: Jonathan Zawadzki

February 11, 2025

Presentation THT Abstracts 2025

Assessing Long-Term Outcomes of Tirzepatide and Semaglutide in Heart Failure With Preserved Ejection Fraction: A Retrospective Cohort Analysis From TrinetX Database

Presenter: Thitiphan Srikulmontri

February 11, 2025

Presentation THT Abstracts 2025

Evaluating the Impact of Sglt2 Inhibitors on Outcomes in Patients With Sarcoidosis and Heart Failure With Preserved Ejection Fraction

Presenter: Emmanuel Otabor

February 11, 2025

Presentation THT Abstracts 2024

Disparities in Guideline Directed Medical Therapy (GDMT) Use and Dosing in Rural (versus Non-Rural) Veterans with Heart Failure with Reduced Ejection Fraction (HFrEF)

Presenter: Alexandra Steverson

March 05, 2024

Presentation THT Abstracts 2024

Effect of Expert Team Consultation for Adjustment of Guideline Directed Medical Therapy on Heart Failure Related Adverse Outcomes in Patients with Reduced Ejection Fraction

Presenter: Joseph Maenza

March 04, 2024

Presentation THT Abstracts 2024

Interim Results from Adaptive Randomized Controlled Trial of Autologous Bone Marrow Mononuclear Cells Using the CardiAMP Cell Therapy System in Patients with Ischemic Heart Failure due to Reduced Left Ventricular Ejection Fraction (HFrEF)

Presenter: Amish Raval

March 04, 2024

Presentation THT Abstracts 2024

Association of a Novel, Non-invasive AI Model to Automate Echocardiographic Detection of Heart Failure with Preserved Ejection Fraction (HFpEF) with Invasive Hemodynamics

Presenter: Nadira Hamid

March 04, 2024

Presentation THT Abstracts 2024

Endovascular Ablation of the Right Greater Splanchnic Nerve in Heart Failure with Preserved Ejection Fraction: Differences in Medication Changes in in the Sham and Treatment groups of REBALANCE-HF

Presenter: Sheldon Litwin

March 04, 2024

Presentation THT Abstracts 2024

Endovascular Ablation of the Right Greater Splanchnic Nerve in Heart Failure with Preserved Ejection Fraction: REBALANCE-HF Stress Blood Volume Analysis †

Presenter: Marat Fudim

March 04, 2024

Advertisement

Beta-Blocker Therapy and Long-Term Outcomes in Heart Failure With Reduced Ejection Fraction After Heart Transplantation: Real-World Evidence

Leveraging Remote Patient Monitoring to Optimize Guideline-Directed Medical Therapy in Heart Failure With Reduced Ejection Fraction

Baroreflex Activation Therapy Improves Cardiopulmonary Exercise Tolerance and Aerobic Capacity in Heart Failure With Reduced Ejection Fraction

Evaluating Glucagon-Like Peptide Agonists and Glucose-Dependent Insulinotropic Polypeptide Receptor Agonists Treatment in Heart Failure With Preserved Ejection Fraction: A Meta-Analysis of Global RCTs

Association of SGLT2 Inhibitors With Clinical Outcomes in Patients With Severe Renal Impairment (Estimated Glomerular Filtration Rate < 30) and Heart Failure With Reduced Ejection Fraction (HFrEF)

Impact of Sitagliptin on Long-Term Outcomes in Heart Failure With Reduced Ejection Fraction in Type 2 Diabetes Patients: A Retrospective Cohort Study

Impact of Psychological Comorbidities on Clinical Outcomes in Heart Failure With Reduced Ejection Fraction (HFrEF)

Assessing Long-Term Outcomes of Tirzepatide and Semaglutide in Heart Failure With Preserved Ejection Fraction: A Retrospective Cohort Analysis From TrinetX Database

Evaluating the Impact of Sglt2 Inhibitors on Outcomes in Patients With Sarcoidosis and Heart Failure With Preserved Ejection Fraction

Disparities in Guideline Directed Medical Therapy (GDMT) Use and Dosing in Rural (versus Non-Rural) Veterans with Heart Failure with Reduced Ejection Fraction (HFrEF)

Effect of Expert Team Consultation for Adjustment of Guideline Directed Medical Therapy on Heart Failure Related Adverse Outcomes in Patients with Reduced Ejection Fraction

Interim Results from Adaptive Randomized Controlled Trial of Autologous Bone Marrow Mononuclear Cells Using the CardiAMP Cell Therapy System in Patients with Ischemic Heart Failure due to Reduced Left Ventricular Ejection Fraction (HFrEF)

Association of a Novel, Non-invasive AI Model to Automate Echocardiographic Detection of Heart Failure with Preserved Ejection Fraction (HFpEF) with Invasive Hemodynamics

Endovascular Ablation of the Right Greater Splanchnic Nerve in Heart Failure with Preserved Ejection Fraction: Differences in Medication Changes in in the Sham and Treatment groups of REBALANCE-HF

Endovascular Ablation of the Right Greater Splanchnic Nerve in Heart Failure with Preserved Ejection Fraction: REBALANCE-HF Stress Blood Volume Analysis †

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content